Pressrelease

2022-04-12 / Last updated : 2022-04-12 adiqb1 Laboratory of Molecular Immunology

Elucidation of the functional ligand of LAG-3, a potential therapeutic target of cancer immunotherapy

Takumi Maruhashi
Daisuke Sugiura
Il-mi Okazaki
Kenji Shimizu
Taku Okazaki
Immunity
  • The ligand of LAG-3, an inhibitory immune co-receptor was controversial.
  • LAG-3 is found to inhibit T cell activation in autoimmunity and anti-cancer immunity by binding to stable complexes of peptide and MHC class II.
  • The interaction between stable peptide–MHC class II and LAG-3 is a potential therapeutic target in human diseases.

 

Pressrelease
(Go to the IQB Japanese Website)

Journals

Journal: Immunity

Title: Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity

Author: Takumi Maruhashi, Daisuke Sugiura, Il-mi Okazaki, Kenji Shimizu, Takeo K Maeda, Jun Ikubo, Harunori Yoshikawa, Katsumi Maenaka, Naozumi Ishimaru, Hidetaka Kosako, Tatsuya Takemoto, and Taku Okazaki

DOI: 10.1016/j.immuni.2022.03.013

URL：https://www.cell.com/immunity/home

Contact

Taku Okazaki

Professor, Institute for Quantitative Biosciences